Anika Therapeutics Inc. (NASDAQ:ANIK) CEO Charles H. Sherwood sold 63,799 shares of Anika Therapeutics stock in a transaction that occurred on Thursday, July 27th. The stock was sold at an average price of $50.79, for a total value of $3,240,351.21. Following the completion of the sale, the chief executive officer now owns 174,705 shares in the company, valued at $8,873,266.95. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Shares of Anika Therapeutics Inc. (NASDAQ ANIK) traded up 1.77% during midday trading on Monday, hitting $51.16. The stock had a trading volume of 120,176 shares. Anika Therapeutics Inc. has a 52-week low of $41.38 and a 52-week high of $53.50. The company has a market cap of $749.90 million, a PE ratio of 22.73 and a beta of 1.68. The company’s 50 day moving average is $47.90 and its 200 day moving average is $46.92.
Anika Therapeutics (NASDAQ:ANIK) last issued its quarterly earnings data on Wednesday, July 26th. The biotechnology company reported $0.76 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.32. Anika Therapeutics had a return on equity of 14.88% and a net margin of 30.44%. The business had revenue of $33.50 million for the quarter, compared to the consensus estimate of $27.20 million. During the same period in the prior year, the business posted $0.57 earnings per share. The company’s quarterly revenue was up 25.9% compared to the same quarter last year. On average, analysts anticipate that Anika Therapeutics Inc. will post $1.91 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “Anika Therapeutics Inc. (ANIK) CEO Charles H. Sherwood Sells 63,799 Shares” was originally reported by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://stocknewstimes.com/2017/07/31/anika-therapeutics-inc-anik-ceo-charles-h-sherwood-sells-63799-shares.html.
Separately, Zacks Investment Research upgraded Anika Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 5th.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in ANIK. Eagle Ridge Investment Management acquired a new position in Anika Therapeutics during the second quarter worth approximately $214,000. Texas Permanent School Fund boosted its position in Anika Therapeutics by 1.0% in the second quarter. Texas Permanent School Fund now owns 10,700 shares of the biotechnology company’s stock worth $528,000 after buying an additional 102 shares in the last quarter. Bbva Compass Bancshares Inc. boosted its position in Anika Therapeutics by 83.8% in the second quarter. Bbva Compass Bancshares Inc. now owns 15,030 shares of the biotechnology company’s stock worth $741,000 after buying an additional 6,852 shares in the last quarter. NGAM Advisors L.P. boosted its position in Anika Therapeutics by 3.8% in the second quarter. NGAM Advisors L.P. now owns 91,309 shares of the biotechnology company’s stock worth $4,505,000 after buying an additional 3,311 shares in the last quarter. Finally, Municipal Employees Retirement System of Michigan boosted its position in Anika Therapeutics by 3.0% in the second quarter. Municipal Employees Retirement System of Michigan now owns 3,450 shares of the biotechnology company’s stock worth $170,000 after buying an additional 100 shares in the last quarter. 81.75% of the stock is currently owned by hedge funds and other institutional investors.
Anika Therapeutics Company Profile
Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.
Receive News & Ratings for Anika Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
